Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velocity study of JNJ-81241459 in moderate to severe plaque psoriasis
ISRCTN76294777Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of JNJ-1459 in plaque psoriasis (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants achieving PASI 75 at Week 12. Started Sep 2024; status: terminated.
02
Drugs
JNJ-1459
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ISRCTN76294777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN76294777.